supp.fit

Docosahexaenoic Acid and Vitamin E: study protocols

18 study groups took Docosahexaenoic Acid together with Vitamin E. These are the doses the studies gave. They are not a recommendation.

Docosahexaenoic Acid: what the research found →

Dose per serving from research: Docosahexaenoic Acid

18 study groups in 16 studies say how much Docosahexaenoic Acid participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg and 500 mg to 1 g and 1 g to 2.5 g, 28% of 18 study groups each.

Daily doseStudy groups
250 mg or less
1
250 mg to 500 mg
5
500 mg to 1 g
5
1 g to 2.5 g
5
2.5 g to 5 g
2

Dose per serving from research: Vitamin E

12 study groups in 10 studies say how much Vitamin E participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 33% of 12 study groups.

Daily doseStudy groups
1 mg to 2.5 mg
2
2.5 mg to 5 mg
0
5 mg to 10 mg
4
10 mg to 25 mg
1
25 mg to 50 mg
2
50 mg to 100 mg
0
100 mg to 250 mg
1
250 mg to 500 mg
0
500 mg to 1 g
2

Commonly used together

17 of 18 study groups took Docosahexaenoic Acid and Vitamin E with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Omega-3 Fatty Acids
12
Fish Oil
5
EPA
4

18 study groups

Study
CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study
2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye
840 mg6 mg3 years127
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18
1.1 g10 mg12 weeks30
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea
720 mg1.5 mg60 days21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea
720 mg1.5 mg60 days21
Improvement of major depression is associated with increased erythrocyte DHA
2013 · HiDHA · Adults receiving treatment for major depression
2 g10 mg16 weeks—
Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial
2020 · DE group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function
465 mg600 IU12 weeks—
The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial
2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition
400 mg10 IU18 weeks134
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis
480 mg7.6 mg12 weeks40
Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
2022 · active group · Cognitively healthy adults aged 65 years and older
430 mg15 mg2 years30
The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment
2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment
4.14 g782 mg26 weeks23
Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial
2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported.
4.14 g782 mg913 days20
Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: a preliminary study
2007 · AA/DHA group · Adults with end-stage liver disease awaiting liver transplantation
1 g200 IU6 weeks5
Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy
2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included
800 mg10 IU8 weeks—
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication.
1.2 g40 mg24 weeks501
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2.
1.2 g40 mg24 weeks201
Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives
2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day
400 mg—120 days24
Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions
2000 · fish oil (FO) · Healthy subjects; age and sex not specified
1.1 g205 mg12 weeks—
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
200 mg400 IU—10
Docosahexaenoic Acid and Vitamin E: study protocols | supp.fit